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AROYLANILINE COMPOUNDS, 
PHARMACEUTICAL COMPOSmONS, AND 
MEmODS OF USING SAME TO INHIBIT 
VIRAL ACTIVITY 
TECHNICAL FIELD OF THE INVENTION 
The present invention is directed, in general, to aroyla-
niline compounds which exhibit antiviral activity, methods 
for synthesizing these aroylaniline compounds, pharmaceu-
tical formulations containing these compounds, and methods 
for treating viral infections, particularly those caused by a 
human immunodeficiency virus, such as HIV. 
More particularly, the present invention is related to 
substantially pure aroylaniline derivatives and related com-
pounds wherein the central double bond is replaced with, for 
example, a methylene-, ethylene-, hetero atom-, amido-, 
ureido- or thioureido-linkage, as well as pharmacological 
uses and compositions thereof. 
BACKGROUND OF THE INVENTION 
Only a decade ago, acquired immune deficiency syn-
drome (AIDS) was virtually unknown. This puzzling afflic-
tion was seen only in a small number of homosexual men. 
However, today it is difficult to find anyone who has not 
heard of AIDS, the disease that can debilitate and then kill 
its victim. 
AIDS is a fatal disease, reported cases of which have 
increased dramatically within the past several years. Esti-
mates of reported cases also continue to rise dramatically. 
Consequently, there is a great need to develop drugs and 
vaccines to combat AIDS. 
The virus which is the causative agent of AIDS was first 
identified in 1983. Since 1983 the AIDS-causing virus has 
been known by several names and acronyms. Most recently, 
it has been referred to as human immunodeficiency virus 
(HIV). It has also been known as lymphadenopathy-
associated virus (LAV) andAIDS-related virus (ARV). HIV 
is the third known T-lymphocyte virus (HILV-III), and it has 
the capacity to replicate within cells of the immune system, 
causing profound cell destruction. The AIDS virus is a 
retrovirus, which is a virus that uses reverse transcriptase 
during replication. Two distinct families of HIV have been 
described to date, namely HIV-1 and HIV-2. The acronym 
HIV will be used herein to refer to HIV viruses generically. 
Thus far, there is no cure for AIDS. 
Specifically, HIV is known to exert a profound cytopathic 
effect on the CD4+ helper/inducer T-cells, thereby severely 
compromising the immune system. HIV infection also 
results in neurological deterioration and, ultimately, in the 
death of the infected individual. 
The field of viral chemotherapeutics has developed in 
response to the need for agents effective against retroviruses, 
in particular HIV. There are many ways in which an agent 
can exhibit anti-retroviral activity. For example, HIV 
requires at least four viral proteins for replication: reverse 
transcriptase (Rf), protease (PR), transactivator protein 
(I'AT), and regulator of virion-protein expression (REV). 
Accordingly, viral replication could theoretically be inhib-
ited through inhibition of any one or all of the proteins 
involved in viral replication. Anti-retroviral agents, such as 
AZf and ddC, are known to inhibit RI'. There also exist 
anti-retroviral agents that inhibit TAT. 
Nucleoside derivatives, such as AZf, are the only clini-
cally active agents that are currently available for antiviral 
therapy. Although very useful, the utility of AZf and related 
compounds is limited by toxicity and insufficient therapeutic 
indices for fully adequate therapy. The development of 
AZT-resistant strains of HIV also limits the utility of AZf in 
the treatment of AIDS. 
2 
Synthetic peptides also are being developed for potential 
use as inhibitors of the retroviral PR in the treatment of 
AIDS. Although these inhibitors are effective in preventing 
the retroviral PR from functioning, the inhibitors suffer from 
5 some distinct disadvantages. First, since the active site of the PR is hindered, i.e., has reduced accessibility as compared to 
the remainder of the PR, the ability of the inhibitors to access 
and bind in the active site of the PR is impaired. Secondly, 
the peptide inhibitors that bind to the active site of the PR are 
generally poorly soluble in water, causing distinct problems 
10 in drug delivery. 
Dyes, particularly azo dyes, have also been discovered to 
exhibit antiviral activity. For example, compounds which 
exhibit potential antiherpes activity include the azo dye 
Trypan Blue (Alarcon et al., "Screening for New Com-
15 pounds with Antihexpes Activity," Antiviral Res., 4 231-243 
(1984); and Thome et al., "Inactivation of Measles and 
Herpes Simplex Viruses by Trypan Blue," J. Gen. Virol., 64, 
1365-1368 (1983)), as well as lndigocarmine and Paraor-
ange (Westin et al., "Aromatic Sulfonic Acids as Inhibitors: 
Structure-Activity Study Using Rhino, Adeno 3, Herpes 
20 Simplex, and Intluenza Viruses," J Med. Chem., 14, (7), 
596-600 (1971)). The azo dye Congo Red and derivatives 
thereof have also been investigated for potential anti-AIDS 
activity (Mohan et al., "Potential Anti-AIDS Agents. Syn-
thesis and Anti-viral Activity of Naphthalenesulfonic Acid 
25 Derivatives Against HIV-1 and HIV-2," J. Med. Chem., 34, 
212-217 (1991)), and the azo dye Evans Blue (Schols et al., 
"Flow Cytometric Method to Demonstrate Whether Anti-
HIV-1 Agent Inhibit Virion Binding to T4+ Cells," J. of 
Acquired Immune Deficiency Syndromes, 2, 10-15 (1989)). 
30 Further, a number of azo dyes were demonstrated to exhibit 
protective properties in mice infected by equine encephalo-
myelitis virus (Hurst et al., Brit. J. Phannacol., 7, 455 
(1952)). Eric De Clercq in Anticancer Research, 7, 1023 
(1987), and in the Int. J. Cancer, 37, 451 (1986), summa-
35 rized the perspectives for the chemotherapy of AIDS. These 
reviews mention two polyanionic dyes with proven anti-HIV 
activity, i.e., Evans Blue, an azo dye, which is available in 
85% purity (Aldrich 1994) and aurintricarboxylic acid 
which has recently been shown to be a polymeric mixture, 
and not a monomeric substance. Other anti-virally active azo 
40 dyes are disclosed in U.S. application Ser. No. 08/167,296. 
Thus, dye compounds have been shown to exhibit antiviral 
activity. 
While the above azo dyes have demonstrated anti-HIV 
activity, they tend to dye the tissues of man or domestic 
45 animals. These staining properties have obvious disadvan-
tages. However, the compounds of the present invention 
were developed based on the discovery that the virucidal 
activity of such compounds was due to the binding on the 
uninfected cells, thus preventing attachment/fusion of the 
50 virus. Therefore, compounds with similar affinities but lack-
ing the chromophoric azo linkages may express similar 
biological activity without the disadvantages associated with 
staining tissue. For example, suramin, an effective agent for 
the treatment of early cases of human African trypanoso-
55 miasis (Burger's Medicinal Chemistry, fourth edition, part 
II, 444) was developed by replacement of an azo linkage 
with an amido linkage. Surarnin, hexasodium sym-bis(m-
aminobenzoyl-m-amino-p-methylbenzoyl-1-naphthyamino-
4,6,8-trisulfonate)carbamide, has no azo linkages. The color 
of suramin is off white (The Merck Index, eleventh edition, 
60 1423). In spite of suramin's disappointing performance in 
AIDS patients (L. D. Kaplan et al., "Lack of response to 
surarnin in patients with AIDS and AIDS-related complex", 
Amer. J. Med., 82, 615-20 (1987)), suramin has been 
investigated in detail (DeClercq, E., "Surarnin: A potent 
65 inhibitor of the reverse transcriptase of RNA tumor viruses", 
Cancer Lett., 8:9-22 (1979); Broder, S., Yarchoan R, 
Collins, J.M. et al., "Effects of surarnin on HILV-IIJ/LAV 
5,681,832 
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infection iresenting as Kaposi's sarcoma or AIDS-related 
complex: Clinical pharmacology and suppression of. v_iral 
replication in vivo", Lancet, 2:627-30 (1985); Balzanm, J. 
Mitsuya H .• DeClercq, E., Broder, S., "Comparative inhibi-
tory effects of suramin and other selected compounds on the 5 
infectivity and replication of human T-cell lymphotropic 
virus (IITLV-III)llymphadenopathy-associated virus (LAV) 
", Int. J. Cancer, 37 :451-7 ( 1986); DeClercq, Suramin in the 
Treatment of AIDS "Mechanism of Action", Antiviral Res., 
7, 1-10 (1987); and Nickel, P. et al., "Potentielle Filarizide, 
10 Arzneimittel Forschung", 36 (II) #8, 1153-57 (1986). 
Mohan ct al. have extensively investigated compounds 
related to suramin. These compounds share the terminal 
naphthalcnesulfonic acid moieties but the substitution pat-
tern of the naphthalenes is different. (Mohan, P. et al., 
"Naphthalenesulfonic acid derivatives. Potential Anti-AIDS 15 
agents", J. Med. Chem, 34(#1), 212-217 (1991); 35(#26), 
4846-4853 (1992). 36(#34), 1996-2003 (1993)). 
In addition to the tissue staining properties of azo dyes, 
Rl 
4 
-continued 
Rl R4 
R2 RS· 
R6 
y is 
R2 
-H, -co, -cs, "D:•' 
- C(=Z)-' 
CC=Z)- R4 
such compounds may form metal chelates and are thus 
20 
R2 
difficult to formulate. 
In view of the above it is desirable to obtain compounds 
which exhibit biological activity such as virucidal activity 
with reduced or no staining iroperties and which are soluble 
and easier to formulate. 
In view of the above, there is a need for compounds which 
exhibit biological activity such as virucidal activity with 
reduced or no staining properties which may be used alone 
25 
or in combination with AZf and/or other agents in the 
treatment of viral infections, particularly AIDS. The iresent 30 
invention seeks to irovide such compounds as well as 
related compositions and methods of using such composi-
tions. These and other objects of the present invention, as 
well as additional inventive features, will be apparent from 
the desaiption of the invention provided herein. 35 
BRIEF SUMMARY OF THE INVENTION 
In accordance with the present invention, it has now been 
discovered that certain compounds, specifically, aroylaniline 
compounds as defined in Formula I below, are capable of 40 
ircvcnting the replication of a virus in a cell, such as a 
human T-ccll, infected with such a virus, without staining 
the tissue. Also, infections of mammals, particularly 
humans, by a virus, particularly a retrovirus such as a human 
immunodeficiency virus, may be effectively treated with the 45 
compounds of Formula I. 
The aroylaniline compounds and related compounds of 
the Jiescnt invention have the following formula: 
(I) 50 
wherein R is -H. -S03.E, -C02.E, -PO(Oh-2E, 
-N02, or a halogen; 
Q is 
55 
60 
65 
RI 
R1, R2, R3, R4, R5 and R6 are each independently -H, 
--OH, a halogen, -NH2, -NHCH3, -N(CH3h, 
-CHO, CH30--, -S03.E, -N02, -C02.E, -PO 
(Oh-2E, -CH20H, -CH2SCH2COR7, -CH2S-
C2H4COR7, -CH 2S-CH(C02 H)CH 2COR7, 
-CH 2 S-CH(C0 2 H)CH 2 C0 2 R 7 , 
-CH2SCH2COzR7, -CH2SC2H4C02R7 or 
SOJH 
W~-
OH 
wherein E represents H, lithium. sodium, potassium, 
ammonium, magnesium, (HOC2 H4)3NH, (CH3)JNH, 
CH3NH(C2H40Hh, (CH3 )4N, or HN-methylglucamine and 
wherein R7 is -H, methyl, ethyl, benzyl, -NH2, 
-NHCH3, or -NHC2H5; 
X is -CHCH-, -CH2CH 2-, -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
-S02-, -NH-, -CH2- or cyclopropyl; 
Z is oxygen or sulfur; and 
n is 1 or 2, but when n is 1, Y is H, 
R2 Rl 
Rl~Rl R2 
\J.._ C(=Z)-' R!li, or 
R2 
and when n is 2, Y is -CO or -CS. 
5,681,832 
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The present invention also provides for a method inhib-
iting replication of a virus, particularly a retrovirus, and 
more particularly a human immunodeficiency virus, specifi-
cally HIV~ 1 or HIV-2 both in vitro and in vivo, by contacting 
cells with the aroylaniline compounds of the present inven- 5 
tion. 
The present invention further provides a method of treat-
ing a mammal, particularly a human, infected with a virus, 
particularly a retrovirus such as a human immunodeficiency 
virus, comprising administering a retrovirally effective 10 
amount of an aroylaniline compound of Formula I. 
Additionally, the present invention provides a method of 
preventing a mammal, particularly a human, from being 
infected with a virus, particularly a retrovirus such as a 
human immunodeficiency virus, comprising administering a 15 
prophylactively effective amount of an aroylaniline com-
pound of Formula I. 
The present invention also provides a method for utilizing 
the aroylaniline compounds of Formula I for screening and 
other diagnostic testing. 20 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts in vitro testing results for anti-HIV activity 
for the present inventive compound of Example 1. 
FIG. 2 depicts in vitro testing results for anti-HIV activity 
for the present inventive compound of Example 3. 
FIG. 3 depicts in vitro testing results for anti-HIV activity 
for the present inventive conipound of Example 13. 
25 
FIGS. 4 depicts in vitro testing results for anti-HIV 30 
activity for the present inventive compound of Example 14. 
FIG. S depicts in vitro testing results for anti-HIV activity 
for the present inventive compound of Example 29. 
FIG. 6 depicts in vitro testing results for anti-HIV activity 35 
for the present inventive compound of Example 32. 
DETAILED DESCRIPTION OF THE 
INVENITON 
The aroylaniline compounds and related compounds of 40 
the present invention have the following formula: 
(I) 
wherein R is -H, -S03 .E, -C02.E, -P0(0)2.2E, 
-N02, or a halogen; 
Q is 
45 
50 
55 
60 
65 
6 
-continued 
y is 
R2 
-H, -CO, -CS, Rl~R3 u_ C(=Z)-0 
R3 C(=Z)- R4 R3 
R1, R2, R3, R4, Rs and R6 are each independently -H, 
--OH, a halogen, -NH2, -NHCH3 , -N(CH3h, 
-CHO, CH30---, -S03 .E, -N02, -C02.E, -PO 
(Oh2E, -CH20H, --CH2SCH2COR7, -CH2S-
C2H4COR7, -CH 2 S-CH(C02H)CH2COR7, 
-CH 2 S-CH(C0 2 H)CH 2 C0 2 R 7 , 
-CH2SCH2C0~7, -CH2SC2H4C02R7 or 
SOJll 
cQN,-
OH 
wherein E represents H, lithium, sodium, potassium, 
ammonium, magnesium, (HOC2H4hNH, (CH3 hNH, 
CH3NH(C2H40H)2 , or HN-methylglucamine and wherein 
R7 is -H, methyl, ethyl, benzyl, -NH2 , -NHCH3 , or 
-NHC2Hs; 
X is -CHCH-, -CH 2 CH 2-, -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
-S02-, -NH-, --CH2- or cyclopropyl; 
Z is oxygen or sulfur; and 
n is 1 or 2, but when n is 1, Y is H, 
and when n is 2, Y is -CO or -CS. 
Preferably, the aroylaniline compounds have the struc-
tural formulas indicated by the compounds identified in 
Table 1. 
COM-
POUND 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
w 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
7 
POSI-
TION 
OF 
XI+ Q Z AMINE RI+ R1/+ 
C,H,11 U 0 
C,H,fl U 0 
C,H,11 U 0 
C,H,11 U 0 
S0/1 U 0 
C,H,fl U 0 
CH/1 U 0 
S0/1 U 0 
C,H,11 U 0 
C,H.J2 U 0 
NHCONH/l U 0 
1,2-<:ycle>-
propyl/1 
C,H,11 
C,H,11 
C,H.Jl 
C,H,11 
1,2-eycl<>-
propyl/l 
Sil 
C,H,11 
C,H,11 
C,H.Jl 
S0/1 
Sil 
C,H,11 
C,H.Jl 
C,H,fl 
C,H..tl 
C,H,11 
C,H,11 
C,H,11 
C,H,11 
C,H,11 
u 0 
u 0 
u 0 
u 0 
u 0 
u 0 
u 0 
u s 
u s 
u s 
u s 
u s 
N 0 
N 0 
N 0 
N 0 
N 0 
p 0 
p 0 
p 0 
p 0 
p 0 
p 0 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
2 
2 
2 
2 
2 
1 
1 
1 
so3-12 
so3-12 So3-12 
So3-12 
co2-13 
so3-12 
C02/3 
so3-12 
so3-12 
so3-12 
so3-12 
co2-12 
so,-12 
so,-12 
so,-12 
so,-12 
so,-12 
so,-12 
so3-12 
so3-12 
so3-12 
so3-12 
so3-12 
so3-12 
so3-12 So3-12 
so,-12 
so3-12 
so3-12 
co2-12 
co2-13 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/8 
OH/l 
OH/l 
OH/1 
OH/1 
OH/l 
co2-12 
co2-12 
co2-12 
S03 -12 S03 -12 
5,681,832 
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R,I+ 
So3-15 
so3-15 
S03-15 
H 
so3-15 
CH0/5 
so3-15 
so3-15 
S03-15 
CH20H/5 
S03-15 
Cl/5 
CH2SCAC02 -15 
CH,SCH,co, -15 
CH2S-CH(Co2-) 
CH2co2-15 
CH2 S -CH2C02CH,15 
CH,S-CH2 CONH,t5 
CH,SCH,CONHCHJ5 
H 
CH2SCH,C02 -15 
CH2SC2ff.C02 -15 
CH,SCH,CONHf5 
CH,SCH,C02CHJ5 
CH2SCAC02 -14 
CH,SCH,co, -/4 
CH,SCH,CO,CHJ4 
CH2SCH,CONH/4 
CH2SCA --CONHCH,14 
OH/3 
OH/3 
OH/3 
Noles: u = QUINOLINE; N = NAPHTHillNE; p = PHENYL; + = POSmON 
The aroylaniline compounds of Formula I, particularly 
compounds 1-12 in Table 1, are prepared by reacting the 60 
requisite aromatic acid (ID) with the aniline compounds (II). 
65 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H Cl/2 
H Cl/4 
H H 
H OCH,14 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
H H 
OH/6 
OH/6 
OH/6 
H 
H 
H 
8 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
u 1 
H 1 
co 2 
u 1 
u 1 
u 1 
u 1 
u 1 
u 1 
u 1 
u 1 
u 1 
u 
u 
u 
u 
u 
u 
u 
u 
u 
u 
u 
N 
N 
N 
H 
H 
p 
p 
p 
p 
p 
p 
SALT 
Na 
Na 
Na 
Na 
K 
Na 
NH.. 
Li 
(CH3)3NH 
NH.. 
K 
(CH3 )•N 
Na 
Na 
(HOC,H.hN 
H 
NH.. 
Na 
Na 
Na 
NH.. 
NH.. 
Li 
Li 
Na 
NH.. 
Na 
(CH3 )•N 
Na 
Na 
Na 
K 
Na 
Na 
Na 
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Preferably, the aromatic acid (Ill) is first activated by 
converting the acid into a symmetric anhydride, mixed 
anhydride, active ester, or acid chloride, by using N,N-
di eyclohex ylc arb odiimi de (DCC) and 
N-hydroxybenzotriazole (HBT) as activating agents. Addi- 5 
tional routes toward amides are well documented in Barton's 
Comprehensive Organic Chemistry, vol. II, 958, Pergamon 
1979, and in T. W. Greene's Protective Groups in Organic 
Chemistry, J. Wiley & Sons, New York 1991. When using 
DCC and HBT as coupling agents, DMF is the preferred 
solvent. The reaction can be conducted at elevated tempera- 10 
ture for shorter periods, but room temperature is preferable. 
Reaction times may vary from one to eight days. To assure 
optimal yields of the desired aroylaniline compounds and a 
minimum of by-products, the reaction is preferably con-
ducted for a maximum of eight days. 
-OR-Q- COClz > Q-C(=Z)NH " j X \. i NH2 -
R 
10 
-continued 
~ 
llN~C(}z 
OH 
(VI) 
Compounds of Formula I, wherein n is 2 and Y is -CO, 
such as Compound 3 in Table 1, are synthesized by carbo-
nylation of compounds I, where n is 1 and Y is H, using 
either phosgene, triphosgene or carbonyldiimidazole as a 
reagent, as shown below for the synthesis of compound 3. 
NH-C-HN 
II 
The key intermediate for quinolinoyl-substituted anilines 
is prepared starting with the commercially available 
8-hydroxyquinoline-5-sulfonic acid (IV), which is formy-
lated for example using the Du1f reaction to furnish 
8-hydroxyquinoline-7-formyl-5-sulfonic acid (V). Potas-
sium permanganate oxidation of the product under basic 
conditions yields 8-hydroxyquinoline-5-sulfo-7-carboxylic 
acid (VI) which is then coupled with an aniline compounds 
(II) using HBT and DCC as activating agents to furnish the 
quinoline compounds of Formula I. 
0 
Thio-Mannich products, ie., Formula I, (where n is 1, R2 
is --CH2SCH2COR7 , --CH2S--C2H4 COR7 , --CH2S--CH 
40 (C02H)CH2COR7 , CH2S--CH(C02H)CH2CO;iR.7 , and Y is 
phenyl, quinoline or naphthalene ring structure as defined 
above) are obtained by reacting compounds of Formula I, 
wherein at least one R1-R6 substituent is a hydroxy group 
with a hydrogen at its ortho or para position (such as 
45 compounds 13-18 in Table 1), with formaldehyde and the 
appropriate mercaptoalkanoic acid derivative (VII). The 
reaction temperature may vary from room temperature to 
100° C. The reaction time may vary from one to ten hours. 
The preferred time is about three hours at 100° C. 
50 
1. N4(CH2)6 > WSOJll 
2.HCVlhr 
CHO 55 
I+ CH20 + VIl 
iOH-
(IV) 
~ llN~CHO 
OH 
M 
M 
1. KMnO., OH- > 
2.H+ 
OH 
where acid derivative (VII) is HSCH2COR7 , HSC2H4 COR7 , 
HSCH(C02H)CH2COR7 , HSCH2CO;iR.7 , HSC2H4C02R7 , 
60 
HSCH(C02H)CH2C02_R7 , and R2 is -CH2SCH2COR7
7
, 
-CH2S-C02H4 COR', --CH2S-CH(C02H)CH2COR , 
CH 2S-CH(C02H)CH2C0 2R7 , -CH2SCH2C02R7 , 
-CH2SC2H4C02R7 • Quinoline substituted compounds (I), which have a thioa-
mide (CSNH) linkage, are prepared by reacting 
65 8-hydroxyquinoline with o-ethylxanthic acid (potassium 
salt) at elevated temperatures in an autoclave to obtain 
8-hydroxyquinoline-7-thioacid. The preferred temperature 
5,681,832 
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range is 130°-180° C. Coupling of this compound to aniline 
derivatives (II), in the presence of DCC/HBT yields thioa-
mide linked quinolines, such as Compounds 19-23 in Table 
1. The last step of the sequence is illustrated by the prepa-
ration of Compound 19. 5 
Thioamides may also be prepared by reacting amides with 
the climcr of p-methoxyphenylthiono phosphine sulfide, 
Lawesson's Reagent. 
OH 
('~~CSiH 
2~ +H?N 
25 
NHz DCC, HBT > 
DMF,R.T. 
6days 
-continued 
x 
Compounds (I) which have hydroxynaphthalene groups 
as terminal substituents, such as Compounds 24-28 in Table 
1, can be reacted with mercaptoalkanoic acids, esters or 
amides and formalin to give the corresponding thio-Mannich 
30 products with the carboxy-, alkoxycarbonyl- or amidoalky-
OH 
~co, 
vy H 
lthiomethyl group at the ortho(para) position (relative to the 
hydroxy group). The reaction time may vary from one to 
twelve hours at temperatures ranging from 50° to 100° C. 
tCH:iO/(VII) 
OH 
R 
R2 
2 
35 where VIl is HSCH2COR7, HSC2H4COR7, HSCH(C02H) 
CH2COR7, HSCH2CO:iR7, HSC2H4C02R7, HSCH(C02H) 
CH2C02R7, and R2 is -CH2SCH2COR7, -CH2S-
C2H4COR7, -CH2S-CH(C02H)CH2COR7, CH2S-CH 
(C0 2 H)CH 2C0 2R 7, -CH 2SCH 2C0 2 R 7 , or 
40 
-CH2SC2H4C02R7. 
Acylation of 4,4'-diaminostilbene-2,2'-disulfonic acid 
disodium salt with 2,3-dihydroxyphthalic anhydride fur-
nishes the ring-opened derivative, Compound 29 in Table 1, 
depicted below. 
¢cCOzH NHY co/ ' I SO:iNa 
OH ' CH=CHO 
SO:iNa I ~ )QOH 
A CO ~ NH/ ~' c 
OH 
The synthesis of Compound 32 in Table 1 is depicted 
below. 
13 
NaO:iS 
SOJNa 
lNaHS.reflux, lbr water/MeOH 
5,681,832 
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SOJNa 
OH 
1. NaN02. HCI. O" C. '~ 
SOJNa 
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The aroylaniline compounds of the present invention act compositions of the present invention. The following meth-
as a chemical barrier to retroviral, particularly HIV, trans- 50 ods and excipients are merely exemplary and are in no way 
mission. Specifically, it is believed that the mechanism of limiting. 
action is that the aroylaniline compounds bind to the CD4+ The aroylaniline compounds of the present invention can 
amino acid region that contains a high concentration of be used in vitro for diagnostic testing and other assays or 
arginine which retorviruses such as HIV typically bind to. screening methods well known to one of ordinary skill in the 
art. For example, the compounds may be used for studying 
The aroylaniline compounds of the present invention can 55 viruses, particularly retroviruses. 
be used in the form of their pharmaceutically acceptable While the method of the present invention can be prac-
salts, can be used alone or in appropriate association, and ticed in vitro, it has particular usefulness in in vivo appli-
can also be used in combination with other pharmaceutically cations. As regards these applications, the present invention 
active compounds. The active agent can be present in the includes the administration to a mammal, particularly a 
phannaceutical composition in any suitable quantity. The 60 human, of a virally effective amount, particularly a retrovi-
phannaceutical excipients described herein, for example, rally effective amount of one or more of the aforementioned 
vehicles, adjuvants, carriers or diluents, are well known to aroylaniline compounds as the active agent effective against 
those who are skilled in the art, and readily available. The a viral infection, such as AIDS and AIDS-related infections. 
choice of excipient will be determined in part by the One skilled in the art will appreciate that suitable methods 
particular compound, as well as by the particular method 65 of administering a compound of the present invention to a 
used to administer the composition. Accordingly, there is a mammal are available, and, although more than one route 
wide variety of suitable formulations of the pharmaceutical can be used to administer a particular compound, a particular 
5,681,832 
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Unit dosage forms for oral administration such as syrups, 
elixirs, and suspensions wherein each dosage unit, e.g., 
teaspoonful or tablespoonful, contains a predetermined 
amount of the aroylaniline compounds. employed in the 
route can provide a more immediate and more effective 
reaction than another route. The compounds may be admin-
istered in any suitable manner, including orally, buccally, 
sublingually. subcutaneously, intramuscularly, intravenously 
or rectally. 
The aroylaniline compounds of the present invention can 
be employed in pharmaceutical compositions and used for 
treating viral infections, particularly retroviral infections. 
For example, the present inventive aroylaniline compounds 
can be used to treat infections by viruses, such as Hepatitis 
B, Hll..V-1, Hll..V-IL Hll..V-N, HfLV-V, HN-1, HN-2, 
HN-3 and HN-4, herpes simplex I, herpes simplex II, 
herpes zoster, Epstein-Barr virus, cytomegalo viruses and 
influenza. 
s present invention can be by a pharmaceutically acceptable 
carrier, such as Sterile Water for Injection, USP, or normal 
saline. 
The term "unit dosage form" as used herein refers to 
physically discrete units suitable as unitary dosages for 
10 human and animal subjects, each unit containing a prede-
termined quantity of the aroylaniline compounds calculated 
in an amount sufficient to produce the desired effect in 
association with a pharmaceutically acceptable, diluent, 
carrier or vehicle. The specifications for the novel unit 
The aroylaniline compounds employed in the present 
invention can be made into pharmaceutical compositions by 
combination with appropriate pharmaceutically acceptable 
carriers or diluents, and may be formulated into preparations 
1s dosage forms of the present invention depend on the par-
ticular compound employed and the effect to be achieved, 
and the pharmacodynamics associated with each compound 
in the host. 
The amount of aroylaniline compound of the present in solid, semi-solid, liquid or gaseous forms such as tablets, 
capsules, granules, powders, solutions, suppositories, 
injections. inhalants, and aerosols in the usual ways for their 
respective route of administration. 
In the case of oral preparations, the aroylaniline com-
pounds can be used alone or in combination with appropriate 
additives to make tablets, powders, granules or capsules, 
e.g., with conventional additives such as lactose, mannitol, 
corn starch or potato starch; with binders such as crystalline 
cellulose, cellulose derivatives, acacia, corn starch or gela-
tins; with disintegrators such as corn starch, potato starch or 
sodium carboxymethylcellulose; with lubricants such as talc 
or magnesium stearate; and if desired, with diluents, buff-
ering agents, moistening agents, preservatives and flavoring 
agents. 
20 invention to be used varies according to the degree of 
infection encountered and the stage of the disease. A suitable 
dosage is that which will result in concentration of the 
aroylaniline compound in blood and/or tissue harboring 
virus which is known to inhibit the virus, e.g., about 10~ 
2.5 to 10-4M, more preferably 10-sM to lO'""°M. The preferred 
dosage is that amount sufficient to beneficially affect a host 
and possibly render the host asymptomatic to the particular 
viral infection. For example, the dosage amount can vary 
between 0.01-5 mg/kg body weight administered 1-5 times 
30 daily. The dose may vary when the compounds are used 
prophylactically. 
Furthermore, the aroylaniline compounds employed in the 
present invention can be made into suppositories by mixing 3.5 
with a variety of bases such as emulsifying bases or water-
soluble bases. The suppository can include vehicles such as 
cocoa butter, carbowaxes and polyethylene glycols, which 
melt at body temperature, yet are solid at room temperature. 
Formulations suitable for parenteral administration 40 
include aqueous and non-aqueous, isotonic, and sterile injec-
tion solutions. The aroylaniline compounds employed in the 
i:resent invention can be formulated into preparations for 
injections by dissolving, suspending or emulsifying them in 
an aqueous or non-aqueous solvent, such as vegetable oil, 4S 
synthetic aliphatic acid glycerides, esters of higher aliphatic 
acids or propylene glycol, and, if desired, with conventional 
additives such as solubilizers, isotonic agents, suspending 
agents, emulsifying agents, stabilizers, thickening agents 
and preservatives. Solution forms can include buffers, such so 
as acetate and phosphate, toxicity adjusting agents, such as 
sodium chloride, pH adjusting agents, such a HQ and 
phosphoric acid. bactericides, solutes that render the solu-
tion isotonic with the blood of the intended recipient, and the 
like. SS 
Extracarpareal injection solutions and suspensions can be 
Jreparcd from sterile powders, granules and tablets of the 
kind i:reviously described. 
In the case of inhalations or aerosol preparations, the 
aroylaniline compounds employed in the invention in the 60 
form of a liquid or minute powder can be utilized in an 
aerosol container with gas or liquid propellants, such as 
dichloroftuoromethane, propane, nitrogen, and the like, and, 
if desired, together with conventional adjuvants such as 
humidifying agents. They can also be formulated as pbar- 6S 
maceuticals for non-pressured preparations such as in a 
nebulizer or an atomizer. 
Any necessary adjustments in dose can be readily made to 
meet the severity of the infection and adjusted accordingly 
by the skilled practitioner. 
The following ·examples further illustrate the present 
invention but, of course, should not be construed as in any 
way limiting its scope. 
EXAMPLES 
Materials and Methods for Synthesizing Aroylaniline Com-
pounds 
In each of the following examples, melting points were 
determined with a Kotler hot stage microscope and are 
corrected. All temperatures are in degrees centigrade. NMR 
spectra were determined with a Varian Gemini-300 (300 
MHz) spectrometer. Chemical shifts (o) were reported rela-
tive to the appropriate deuterated standard. Mass spectra 
were recorded on a VG Analytical 70-SE mass spectrometer 
equipped with an 11-205 J data system. IR spectra were 
recorded on a Nicolet 520 Ff-IR spectrometer. UV spectra 
were recorded on a Shimadzu UV-VIS scanning spectrom-
eter. Elemental analysis was performed by Atlantic 
Microlab, Inc., Norcross, Ga. 
Example 1 
This Example illustrates the synthesis of the aroylaniline 
compound, 4, 4' -di ( 8-hy cir ox y-5- s ulf o- 7 -
quinolinecarboxyamido )stilbene-2,2'disulfonic acid tetraso-
dium salt, Compound 1 as shown in Table 1. 
A. Synthesis of 7-formyl-8-hydroxyquinoline-5-sulfonic 
acid. 
8-Hydroxyquinoline-5-sulfonic acid monohydriate (0.015 
mol, 3.65 g), hexamethylenetetramine (0.225 mol, 21.0 g) 
and acetic acid (750 mL) were stirred and heated at 
97°-100° C. for 6 hrs. After cooling, acetic acid was 
removed under reduced pressure, and the residue was treated 
5,681,832 
17 
with acetone (1 L) to give a precipitate which was filtered off 
and washed with additional acetone. Water (30 mL) and 
concentrated hydrochloric acid (15 mL) were then added to 
the solid. The resulting solution was refluxed for 2 hours. 
Then, the mixture was concentrated under reduced pressure 
and left for crystalliz.ation. The solid was filtered off, washed 
with water and dried to give pure 7-formyl-8-
hydroxyquinoline-5-sulfonic acid in 45% yield. 
m.p. 286°-288° C. 
1H NMR (DMSO-~) o [ppm]: 10.54 (s, lH, H-e) 9.22 
(dd, J=8.7; 1.5 Hz, lH, H-a) 8.99 (dd, J=4.5; 1.5 Hz, lH, 
H-c) 8.17 (s, lH, H-d) 7.84 (dd, J=8.7; 4.5 Hz, lH, H-b) 
18 
1H NMR (D20) o [ppm]: 8.75 (br d, J=8.1Hz,2H, H-a) 
8.67 (br d, J=3.9 Hz, 2H, H-c) 8.54 (s, 2H, H-d) 8.22 (d, 
J=2.1Hz,2H, H-e) 7.89 (d, J=8.7 Hz, 2H, H-g) 7.86 (s, 2H, 
H-h) 7.78 (dd, J=8.4; 1.8 Hz, 2H, H-f) 7.56 (dd, J=8.1; 4.2 
5 Hz, 2H, H-b). 
IR (KBr) Vmax [cm-1]: 3443, 2926, 2855, 1641, 1580, 
1530, 1499, 1451, 1405, 1306, 1190, 1113, 1080, 1061, 
1042, 1025, 761, 703, 624. 
UV (H20) vmax [nm]: 204, 244, 277, 367. 
10 Anal. (C34H~4Na4016S4x9H20) C, H, N, S. 
Example 2 
IR (KBr) v"""' [ cm-1]: 3442, 3109, 2926, 2855, 1657, This Example illustrates the synthesis of the aroylaniline 
1611, 1594, 1552, 1401, 1330, 1282, 1244, 1176, 1126, compound, 4-amino-4'-(8-hydroxy-5-sulfo-7-
1045, 987, 942, 897, 828, 765, 743, 634, 591. 15 quinolinecarboxyarnido)stilbene-2,2'-disulfonic acid triso-
B. Oxidation of 7-formyl-8-hydroxyquinoline-5-sulfonic dium salt, Compound 2 as shown in Table 1. To a solution 
acid of 4,4'-diaminostilbene-2,2'-disulfonic acid disodium salt 
The 7-formyl-8-hydroxyquinoline-5-sulfonic acid (15 (0.5572 mmol, 0.234 g) in DMF (35 mL) a solution of 
mmol, 3.80 g) was dissolved in sodium carbonate solution 7-carboxy-8-hydroxyquinoline-5-sulfonic acid monoso-
(34.5 mmol, 3.66 gin 200 mL of H20). The solution was 20 dium salt (1.114 mmol, 0.324 g) in DMF (65 mL) was 
stirred and heated at 52° C. (oil bath). Then to the hot added. To the mixture 1-hydroxybenzotriazole (HBT)(l.332 
solution potassium permaganate (37.5 mmol, 5.94 g) was mmol, 0.180 g) and then 1,3-dicyclohexylcarbodiimide 
added. The temperature was increased to 68° C. The stirring (DCC) (2.228 mmol, 0.360 g) were added. The reaction 
and heating (60°-65° C.) was continued for 55 minutes. mixture was refluxed under nitrogen for 3 days. Then, 
After that time the reaction mixture was filtered, and the 25 insoluble material was filtered off to give 0.073 g of the 
solid was washed with sodium carbonate solution followed product of 7-carboxy-8-hydroxyquinoline-5-sulfonic acid 
by water. The filtrate was concentrated under reduced monosodium salt self-esterification. The filtrate was evapo-
pressure, acidified with 50% sulfuric acid (pH 3) and left for rated under reduced pressure. Water was added to the residue 
crystallization. The precipitate was filtered off, washed with and insoluble material was filtered off. The filtrate was 
a small amount of water and dried to give 1.96 g of 30 concentrated in vacuo and the pH of solution was adjusted 
7-carboxy-8-hydroxyquinoline-5-sulfonic acid ( 48.5% ). to 9. The solvent was removed under reduced pressure. The 
m.p. 289°-291° C. residue was treated with methanol, insoluble material was 1H NMR (DMSO-di;) o [ppm]: 9.39 (dd, J=8.7; 1.5 Hz, removed by filtration, and the filtrate was concentrated 
lH, H-a) 8.89 ( dd, J=4.5; 1.5 Hz, lH, H-c) 8.33 (s, lH, H-d) under reduced pressure and fractionated on Sephadex LH 20 
7.88 (dd, J=8.7; 4.5 Hz, lH, H-b) IR (KBr) vmax [cm-1]: 35 column using methanol as eluent. Fractionation was 
3408, 3095, 2922, 1673, 1611, 1601, 1547, 1474, 1383, repeatedfornon-homogeneous fractions containing product 
1310, 1228, 1184, 1159, 1109, 1052, 965, 823, 791, 771, This technique allowed for the separation of the pure 
701, 665, 617, 598. monoamide, Compound 2, in 42% yield (0.160 g). 
c._ S!nthesis o! 4,~'-di(8-~y~roxy~5-s?lfo-7- m.p. >3000 c. 
qu~oline~arboxyamido)stilbene-2,2-disulforuc aod tetra- 40 1H NMR (D20) 0 [ppm}: 8.77 (br d, J=8.4 Hz, lH, H-a) 
so .... um s ,t . f 44,-diamin. tilbe 2, di If . 'd 8.67 (br d, J=4.2 Hz, lH, H-c) 8.52 (s, lH, H-d) 8.16 (d, 
.o a so.Ution o , os ne- - su omc acr _2 1 1 ) 6 ( 4 H f H h H ') 7 65 (d disodium salt (2.5 mmol, 1.036 g) in DMF (170 mL) a 1:::: · Hz, H, H-e 7·7 m, H~ - .' H-g, - • -1 · ' 
. . . "' . 'd J-8.4 Hz, lH, H-k) 7.59 (dd, J-8.4, 4.2 Hz. lH, H-b) 7.21 
solution ~f 7-carboxy-8-hydroxyq~oline-5-suuomc acr (d, J=2.4 Hz, lH, H-j) 6.88 (dd, J=8.4; 2.4 Hz, lH, H-1). 
monosodium sal~ (5.0 mmol, 1.456 g) m J?MF (650 mL) was 45 IR (KBr) [ -113444 2956 2925 2854 1635 added To the JDJXture 1-hydroxybenzotrtazole (HBT) (15 0 v"""" cm • • • • ' 
mmoi, 2.027 g) 'was added followed by 1,3- 1605, 1577, 1526, 1498, 1456, 1449, 1405, 1307, 1188, 
dicyclohexylcarbodiimide(DCC)(20.0mmol,4.127 g). The 1140, 1113, 1083, 1049, 1025, 797, 764, 730, 706, 622. 
reaction mixture was stirred at room temperature for 8 days. Anal. (C24H1.sN3Na3011S3x5H20) C, H, N, S. 
After that time the reaction solution was concentrated under 50 
reduced pressure. The precipitate was removed by filtration. Example 3 
The filtrate was evaporated in vacuo. Water was added to the This Example illustrates the synthesis of 1,3-di[2,2' -
residue and the mixture was evaporated under reduced disulfo-4(8-hydroxy-5-sulfo-7-quinoline)]stilbene urea, 
pressure. Next the residue was extracted with chloroform hexasodium salt, Compound 3 as shown in Table 1. 
(3x). Insoluble material was filtered off and treated with 55 AsolutionofthemonoamidefromExample2above(0.07 
methanol, with its pH being adjusted to 8. A small amount mmol, 0.048 g) and triethylarnine (0.2 mL) in DMF (50 mL) 
of insoluble material was removed by filtration. The metha- was added dropwise over 20 minutes to a solution of 
nol solution was used for fractionation on Sephadex LH-20 triphosgene (0.14 mmol, 0.042 g) in DMF (5 mL) stirred at 
column using methanol as the eluent. This technique 5°-10° C. Then, the reaction mixture was stirred and heated 
allowed for the separation of pure diamide in 20% yield. The 60 at 120° C. for 6 hours followed by evaporation under 
fractionation was repeated for non-homogeneous fractions reduced pressure. The solid was treated with methanol, and 
containing the desired compound together with a small the pH of the methanol solution was adjusted to 8. The 
amount of monoamide. Finally, the pure diamide was sepa- material was filtered, and filtrate was concentrated and used 
rated from the reaction mixture in 25% yield. Its substituents for fractionation on Sephadex LH-20 column, with the 
and their position of attachment are shown in Table 1, under 65 eluent being methanol. All fractions were analyzed by 1H 
Compound 1. NMR spectroscopy. This technique allowed for the obtain-
m.p. >300° C. ing of the desired product, Compound 3. 
5,681,832 
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m.p. >300° c. 
1H NMR (020) o [ppm]: 8.75 (br d, J=8.l Hz, 2H, H-a) 
8.68 (br d, J=3.0 Hz, 2H, H-c) 8.53 (s, 2H, H-d) 8.20 (br s, 
2H. H-e) 7.83, 7.59 (2 m. 16H, H-b, H-f-H-1). 
20 
(ill), the quinoline compounds of Compounds 5-12 as 
shown in Table 1 are obtained. 
Example 13 
IR (KBr) Vmax [cm-1]: 3439, 2961, 2926, 2850, 1735, 5 
1660, 1460, 1397, 1193, 1139, 842, 631. This Example illustrates the synthesis 4,4'-di[5-(2-
c arb oxyeth ylthiomethyl)- 8-hydroxy-7 -
quinolinecarboxyamido ]stilbene-2,2'-disulfonic acid tetra-
sodium salt, Compound 13 as shown in Table 1, by 
Example 4 
This Example illustrates the synthesis of the aroylaniline 
compound, 4,4'-di(8-hydroxy-7-quinolinecarboxyamido) 
stilbene-2,2'-disulfonic acid disodium salt, Compound 4 as 
shown in Table 1. 
A. Carboxylation of 8-hydroxyquinoline 
Potassium salt of 8-hydroxyquinoline (25 mmol, 4.58 g), 
DMF (50 mL) and an excess of dry ice were heated in a 
pressure reactor at 120° C. for 12 hours. After cooling, water 
(150 ml.) was added to the reaction mixture. The insoluble 
material was filtered o1f. and the filtrate was evaporated 
under reduced pressure. To the residue, water was added 
again, and additional insoluble material was collected by 
filtration. The filtrate was acidified to pH 4 with concen-
trated hydrochloric acid. The i:recipitate was filtered o1f, 
washed with water and dried to give 7-carboxy-8-
hydroxyquinoline in 30.4% yield (1.44 g). 
m.p. 264°-266° c. 
1H NMR (DMSO-dJ o [ppm]: 8.91 (dd, J=4.8; 1.5 Hz, 
lH, H-a) 8.61(dd,J=8.4;1.5 Hz, lH, H-c) 7.91 (d,J=8.4 Hz, 
lH, H-e) 7.80 (dd, J=8.4; 4.5 Hz, lH, H-b) 7.31 (cl, J=8.7 Hz, 
lH, H-d). 
IR (KBr) vmax [cm-1] 3429, 3081, 2932, 1644, 1589, 
1549, 1480,1458,1420,1383,1333,1203, 1150,1114,936, 
874, 846,830,800, 763, 690, 644.600. 
B. Synthesis of 4,4'-di(8-hydroxy-7-
quinolinecarboxyamido )stilbene-2,2'-disulfonic acid diso-
dium salt 
10 
2-carboxyethylthiomethylation of the diamide of Example 4. 
The above diamide, Compound 4, (0.3 mmol, 0.227 g), 
3-mercaptopropionic acid (0.63 mmol, 0.0669 g), formalin 
(0.66 mmol, 0.0198 g), and an aqueous solution of NaOH 
(1.23 mmol, 0.0492 g/3 mL of H20) were refluxed under 
15 nitrogen for 1.5 hours. Then, more formalin (0.33 mmol, 
0.01 g) was added, and refluxing was continued for 30 
minutes. After cooling, a very small amount of insoluble 
material was filtered o1f. The filtrate was evaporated under 
reduced pressure. The residue was treated with methanol, 
20 and the pH of the solution was adjusted to 8. A methanol 
soluble material was used for fractionation on a Sephadex 
LH-20 column, with the eluent being methanol. This tech-
nique allowed the separation of the pure product, Compound 
13, in 51.5% yield (0.16 g). 
25 m.p. >300° c. 
1H NMR (020) o [ppm]: 8.55 (br d, J=3.3 Hz, 2H, H-a) 
8.22 (br s, 2H, H-e) 8.12 (br d, J=8.4 Hz, 2H, H-c) 7.69 (s, 
2H, H-h) 7.54 (d, J=8.7 Hz, 2H, H-g) 7.46 (s, 2H, H-d) 7.39 
(m, 4H, H-b, H-f) 3.60 (s, 4H, H-i) 2.53 (t, J=7.2 Hz, 4H, 
30 H-j) 2.31 (t, J=7.2 Hz, 4H, H-k). 
IR (KBr) vmax [cm-1]3449, 2924, 2860, 1636, 1576, 
1544, 1527, 1504, 1491, 1458, 13991310, 1217, 1181, 1141, 
1080, 1024, 824, 769, 735, 707,629. 
Examples 14-18 
Following the procedure of Example 13 and reacting the 
diamide of Example 4 having the appropriate X-substituents 
with formaldehyde and the appropriate mercaptoalkanoic 
40 acid, mercaptoalkanoic acid ester or mercaptoalkanoic acid 
amide, the quinoline compounds of Compounds 14-18 were 
obtained. 
To a solution of 4,4'-diaminostilbene-2,2'-disulfonic acid 
disodium salt (2.5 mmol, 1.036 g) in DMF (170 mL) a 35 
solution of 8-hydroxyquinoline-7-carboxylic acid 
(5.0mmol, 0.946 g) in DMF (140 mL) was added. To the 
mixture. 1-hydroxybenzotriazole (HBT) ( 6.0 mmol, 0.811 g) 
was added followed by 1,3-dicyclohexylcarbocilmide 
(DCC) (12.0 mmol, 2.476 g). The reaction mixture was 
stirred at room temperature for 6 days. Then, the solution 
was concentrated under reduced pressure. The precipitate 
was filtered o1f. The filtrate was evaporated in vacuo. To the 
residue, water and methanol (1:4) were added, and the pH· 
was adjusted to 8. The insoluble material was filtered o1f, 45 
and the filtrate was evaporated under reduced pressure. The 
residue was extracted with cholorofonn (3x). The solid was 
collected by filtration, and treated with methanol. Insoluble 
material was filtered off and dried to give 0.8 g of pure, 
desired diamide. The methanol solution was used for frac-
tionation on a Sephadex LH-20 column, with the eluent 50 
being methanol. This method allowed for the separation of 
Example 19 
This Example illustrates the synthesis of the aroylaniline 
compound, 4,4'-di(8-hydroxy-7-quinolinethioamido) 
stilbene-2,2'-disulfonic acid disodium salt, Compound 19 
shown in Table 1. 
A. Synthesis of 7-thiocarboxy-8-hydroxyquinoline 
A mixture of 8-hydroxyquinoline (0.055 mol, 8.0 g) and 
0-ethylxanthic acid potassium salt (0.056 mol, 9.0 g) in abs. 
EtOH (20 mL) was placed in a pressure reactor and heated 
at 160° C. for 40 hours. After cooling, the reaction mixture 
was washed with a small amount of EtOH. The insoluble 
an additional 0.59 g pure diamide (yield 73.5%) and traces 
of monoamide. 
m.p. >3000 c. 
1H NMR (020) o [ppm]: 8.55 (d, J=3.0 Hz, 2H, H-a) 8.16 
(d, J=2.1 Hz, 2H, H-f) 7.98 (br d, J=8.1 Hz, 2H, H-c) 7.78 
(m, 6H, H-e, H-h, H-i) 7.61 (dd, J=8.4; 2.1 Hz, 2H, H-g) 
7.33 (dd, J=8.4; 4.2 Hz, 2H, H-b) 6.79 (d, J=8.7 Hz, 2H, 
H-d). 
IR (KBr) vmax [cm-1]3452, 2958, 2925, 2854, 1635, 
1590, 1578, 1527, 1503, 1491, 1453, 1404, 1304, 1218, 
1186.1134,1109,1081,1024,825,796.779, 738,711,630. 
Anal. (C24H2:zN°4N~016S2x6H20) C, H, N, S 
Examples 5-12 
Following the i:rocedures set forth in Example 1 and 
acylating amine (II) with the appropriate, activated acid 
55 material was filtered o1f and treated with aqueous hydro-
chloric acid. The insoluble thioacid was separated by filtra-
tion and purified by heating with barium carbonate in water. 
The mixture was filtered o1f, the filtrate was acidified with 
hydrochloric acid, and precipitate was collected by filtration 
60 to give 7-thiocarboxy-8-hydroxyquinoline (2.61 g) in 18.4% 
yield. 
m.p. 174°-175° c. 
1H NMR (DMSO-d6) o [ppm]: 9.06 (m, 2H, H-a, H-c) 
9.00 (d, J=9.0 Hz, lH, H-e) 8.06 (dd, J=8.4; 5.4 Hz, lH, H-b) 
65 7.58 (d, J=9.0 Hz, lH, H-d). 
IR (KBr) Vmax [cm-1]: 3471, 3090, 3064, 3038, 2965, 
2922, 1630, 1606, 1585, 1541, 1499, 1474, 1417, 1402, 
5,681,832 
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1373, 1319, 1287, 1242, 1225, 1197, 1176, 1138, 1111, 
1049, 1013, 997, 982, 972, 874, 824, 811, 794, 780, 766, 
718, 670. 
B. Synthesis of 4,4'-di(8-hydroxy-7-quinolinethioamido) 
stilbene-2,2'-disulfonic acid disodium salt 
To a solution of 4,4'-diaminostilbene-2,2'-disulfonic acid 
disodium salt (1.0 mmol, 0.414 g) in DMF (70 mL) a 
solution of 8-hydroxyquinoline-7-thiocarboxylic acid (2.0 
mmol, 0.443 g) in DMF (330 mL) was added. To the 
mixture, 1-hydroxybenzotriazole (HBT) (2.4 mmol, 0.324 
g) was added followed by 1,3-dicyclohexylcarbodiimide 
(DCC) (4.8 mmol, 0.990 g). The reaction mixture was stirred 
at room temperature for 6 · days. Then, the solution was 
evaporated under reduced pressure. To the residue, water 
and methanol (1:4) were added, and the pH was adjusted to 
8. The insoluble material was filtered off, and the filtrate was 
evaporated under reduced pressure. The residue was 
extracted with chloroform (3x). The solid was collected by 
filtration and treated with methanol. The methanol solution 
was used for fractionation on a Sephadex LH-20 column, 
with the eluent being methanol. The fractions containing the 
pure, desired product of Compound 19 were combined and 
evaporated under reduced pressure (yield 17%). 
m.p. >300° c. 
1H NMR (D20) a [ppm]: 8.55 (dd, J=4.2; 1.5 Hz, 2H, 
H-a) 8.16(d,J=2.1Hz,2H, H-e) 7.98 (dd, J=8.4; 1.5 Hz, 2H, 
H-c) 7.78 (m, 6H, H-e, H-h, H-i) 7.61 (dd, J=8.4; 2.1Hz,2H, 
H-g) 7.33 (dd, J=8.4; 4.5 Hz, 2H, H-b) 6.79 (d, J=8.7 Hz, 
2H, H-d). 
IR (KBr) vm= [cm-1]: 3467, 2923, 2855, 1635, 1591, 
1527, 1502, 1490, 1452, 1403, 1303, 1214, 1183, 1132, 
1109, 1079, 1023, 891, 824, 796, 779, 737, 711, 629. 
Examples 2~23 
22 
1H NMR (D20) a [ppm]: 8.26 (m, 2H, H-a) 8.10 (d, J=2.1 
Hz, 2H, H-g) 7.75 (m, 4H, H-f, H-j) 7.70 (d, J=8.7 Hz, 2H, 
H-i) 7.57 (m, 2H, H-d)7.52 (dd, J-8.7;2.1Hz,2H, H-h) 7.34 
(m, 4H, H-b, H-c) 6.90 (cl, J-9.0 Hz 2H, H-e) 
5 IR (KBr) v,,.,,,. [cm-1]: 3439, 2924, 2854, 1631, 1594, 
1525, 1505, 1469, 1392, 1359, 1300, 1247, 1208, 1082, 
1026, 809, 790, 761, 726, 707,632, 542. 
4,4' -di [ 4-(2-carboxyethy lthiomethy 1)-1-hydroxy-2-
naphthamido ]stilbene-2,2'-disulfonic acid tetrasodium salt 
10 The above diamide (0.3 mmol, 0.226 g), 
3-mercaptopropionic acid (0.63 mmol, 0.0669 g), formalin 
(0.66 mmol, 0.0198 g), and aqueous solution ofNaOH (1.23 
mmol, 0.0492 g/3 mL of H20) were refluxed under nitrogen 
for 1.5 hours. Then, more formalin (0.33 mmol, 0.01 g) was 
15 added and refluxing was continued for a further 30 minutes. 
After cooling, a small amount of insoluble material was 
filtered off. The filtrate was evaporated under reduced pres-
sure. The residue was treated with methanol, and the pH of 
the solution was adjusted to 8. Methanol soluble material 
20 was used for fractionation on a Sephadex LH-20 column, 
with the eluent being methanol. This method allowed for the 
separation of the pure Compound 24 in 41.9% yield (0.13 g). 
m.p. >300° c. 
1H NMR (D20) B [ppm]: 8.32 (br d, J=7.8 Hz, 2H, H-a) 
25 8.17 (d, J=2.4 Hz, 2H, H-f) 7.86 (br d, J=8.1 Hz, 2H, H-d) 
7.75 (m, 4H, H-h, H-i) 7.63 (m, 4H, H-e, H-g) 7.53 (m, 2H, 
H-b) 7.41 (m, 2H, H-c) 3.94 (s, 2H, H-j) 2.62 (t, J=7.2 Hz, 
2H, H-k) 2.38 (t, J=7.2 Hz, 2H, H-1). 
IR (KBr) Vmax {cm-1]: 3558, 3380, 2924, 2854, 1632, 
30 1576, 1524, 1490, 1427, 1399, 1308, 1193, 1140, 1081, 
1026, 764, 727, 708, 627. 
Examples 25-28 
Following the procedure set forth in Example 19 and 35 
reacting the appropriate dithioamides with formaldehyde 
and the appropriate mercaptoalkanoic acid, mercaptoal-
kanoic acid ester or mercaptoalkanoic acid amide, the quino-
Following the procedure of Example 24 and reacting the 
appropriate diamides with formaldehyde, and the appropri-
ate mercaptoalkanoic acid, mercaptoalkanoic acid ester or 
mercaptoalkanoic acid amide, the napththalene Compounds 
25-28 are obtained. 
line Compounds 2~23 were obtained. 
40 Example 29 
Example 24 This Example illustrates the synthesis of the aroylaniline 
This Example illustrates the synthesis of the aroylaniline compound, 4,4'-di(2-carboxy-3,6-dihydroxybenzamido) 
derivative, 4,4'-di[ 4-(2-carboxyethylthiomethyl)-1- stilbene-2,2'-disulfonic acid disodium salt, Compound 29 as 
hydroxy-2-naphthamido]stilbene-2-2'-disulfonic acid tetra- 45 shown in Table 1. 
sodium salt, Compound 24 as shown in Table 1. A. Hydrolysis of 2,3-dicyanohydroquinone 
A. Synthesis of 4,4'-di(l-hydroxy-2-naphthamido)stilbene- 2,3-Dicyanohydroquinone (29 mmol, 4.7 g) was mixed 
2-2'-disulfonic acid disodium salt into 50% KOH (40 mL). The mixture was heated under 
To a solution of 4,4'-diaminostilbene-2,2'-disulfonic acid nitrogen to reflux for 1.5 hours, then cooled to room tem-
disodium salt (2.0 mmol, 0.829 g) in DMF (140 mL) a 50 perature. The mixture was neutralized with aqueous H2S04 
solution of 1-hydrdoxy-2-naphthoic acid (4.0mmol, 0.753 g) and then extracted with ethyl acetate (5x100 mL). Evapo-
in DMF (60 mL) was added. To the mixture, ration of the solvent and then careful crystallization from 
1-hydroxybenzotriazole (HBT) (5.0 mmol, 0.676 g) was water gave the diacid, mp 216°-219° C. (dee). Yield 3.0 g 
added followed by 1,3-dicyclohexylcarbodiimide (DCC) (52%). 1H-NMR (DMSO, ppm) 6.8 (s, lH). Ff-IR (KBr, 
(10 mmol, 2.060 g). The reaction mixture was stirred at 55 cm1) 3249, 1706, 1667, 1450, 1192. 
room temperature for 7 days. Then, the precipitate was B. Anhydride Formation 
filtered off, and the filtrate was evaporated under reduced The above diacid (1.0 g) was heated in a vacuum subli-
pressure. To the residue, water was added, and the solvent mation apparatus to 230° C. using tap water as the cooling 
was removed in vacuo. Next, the residue was extracted with source and an aspirator vacuum. The sublimed material was 
chloroform (3x). The solid was collected by filtration and 60 a sulfur yellow solid which was recrystallized from benzene. 
treated with methanol, and the pH of the solution was Yield was virtually quantitative. 1H-NMR (DMSO, ppm) 
adjustedto8.Themethanolsolutionwasconcentratedunder 7.2 (s, lH). Ff-IR (KBr, cm-1) 3600, 1827, 1751, 1490, 
reduced pressure and used for fractionation on a Sephadex 1385, 1306, 1197, 894. EIMS: 180 (100), 162 (75), 136 (21), 
LH-20 column, with the eluent being methanol. This tech- 134 (519). 
nique allowed for the separation of the pure desired diamide 65 C. Condensation 
in 49% yield (0.74 g). 4,4'-Diaminostibene-2,2' disulfonic acid disodium salt 
m.p. >300° C. (0.4 mmol, 0.1 g) was stirred in DMF (20 mL) containing 4 
5,681,832 
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A molecular sieves overnight. Afterwards, the anhydride 
(0.16 g) from Part B above was added, and the mixture was 
stirred at 70° C. for 2 hours. After cooling and filtering, 
acetone was added, and the solid was collected and washed 
with copius amounts of acetone. After addition to 0.044 g of 5 
NaHC03 in 10 mL of water, the crude material was lyo-
philized to give the diamide of Compound 29, as shown in 
Table 1, as a light brown powder. 1H-NMR (DMSO, wm) 
9.82 (s, lH), 8.18 (d, lH, J=2 Hz), 7.99 (s, lH), 7.63 (dd, lH, 
J=2. 8 Hz). 7.50 (d, lH, J=8 Hz). 6.72 (d, lH, J=8 Hz), 6.55 10 
(d, lH, J=8 Hz). Ff-IR (KBr, cm-1 ) 3400 (B), 1631, 1589, 
1384. 1083. 1026, 632. 
Examples 30--31 
15 Following the procedure set forth in Example 29 and 
reacting the awropriate aniline (Il) with the anhydride of 
Example 29, Part B, Compounds 30--31 were obtained. 
24 
acetate. 1H NMR (DMSO-~) o [ppm]: 11.6 (lH, s), 8.90 
(lH, d, J=8.2 Hz), 8.54 (lH, d, J=2.2 Hz), 8.33 (lH, s), 8.25 
(lH, s, J=small), 8.05 (lH, s), 8.03 (lH, d, J=small), 7.86 
(lh, d, J=8.3 Hz), 7.84 (lH, dd, J 1=7.7 Hz, J2=small), 7.76 
(lH, d. J=7.7 Hz), 7.60 (lH, dd, J1=8.1 Hz, J2=small), 7.44 
(lH, dd, J 1=8.2 Hz, J2=4.3 Hz). The compound's substitu-
ents and their position of attachment are shown in Table 1. 
Examples 33-34 
Following the procedure set forth in Example 32 and 
coupling the appropriate diazonium salt derived from the 
appropriate aniline (Il) with 8-hydroxyquinoline-5-sulfonic 
acid, Compounds 33-34 are obtained. 
Example 35 
The aroylaniline compounds of the present invention were 
subjected to in vitro screening to determine their anti-IIlV 
activity. 
The National Cancer Institute's procedure for testing for Example 32 
This Example illustrates the synthesis of the aroylaniline 
compound, N.N' -Bis( 4-amino-2-sulfobenzoyl)-4,4' -
diaminostilbene-2,2-disulfonic acid tetrasodium salt, Com-
pound 32 as shown in Table 1. 
20 agents active against Human Immunodeficiency Virus (IIlV) 
(Weislow, 0. W. et al., "New soluble-formazan assay for 
IIlV-1 cytopathic effects: application to high-flux screening 
of synthetic and natural products for AIDS-antiviral 
A. N,N'-Bis( 4-nitro-2-sulfobenzoyl)-4,4'-diaminostibene 25 
-2,2'-disulfonic Acid Testrasodium Salt 
4-Nitro-2-methylsulfonate benzoyl chloride (0.6 g, 2.0 
mmol) was dissolved in ice-cold dry acetonitrile (15 ml). 
This solution was added dropwise to a solution of 4,4' -
diaminostilbene-2,2'-disulfonic disodium salt (504 mg, 1.0 30 
mmol) in water (25 ml) at 0° C. The reaction mixture was 
carefully kept at pH 7 with the addition of a dilute sodium 
hydroxide solution and stirred for two hours in an ice bath. 
A small amount of insoluble materials was filtered off, and 
the clear yellow solution was freeze-dried to give a mixture 35 
containing mainly the product. Gel filtration on Sephadex 
G-25 with water yielded 0.95 g (96%) of the pure product. 
1H NMR (DMS()..(4) o [ppm]: 11.0 (lH, s), 8.61 (lH, d, 
J=2.3 Hz), 8.31 (lH, dd, J1=8.4 Hz, J2=2.3 Hz), 8.05 (lH, s), 
8.03 (lH, d. J=2.2 Hz), 7.96 (lH, d. J=8.3 Hz), 7.78 (lH, dd, 40 
J1=8.4 Hz. J2=2.2 Hz), 7.61 (lH, d, J=8.7 Hz). 
B. N,N'-Bis(4-amino-2-sulfobenzoyl)-4,4'-diaminostilbene 
-2,2-disulfonic Acid Tetrasodium Salt 
To a sodium hydrogen sulfide solution the product from 
Part A (0.9o g) was added and the solution was refluxed for 45 
45 minutes. Hydrochloric acid was added to the solution 
until the pH reached 6, and then the solvent was evaporated 
under reduced pressure. Water (200 mL) was added, and the 
resulting precipitate was collected by filtration and washed 
with water to give 0.45 g (53%) of the title compound. 1H 50 
NMR (DMS()..(4) 0 [wm]: 11.7 91H, s), 8.00 (lH, s), 7.93 
(lH, d, J=2.2 Hz), 7.80 (lH. dd. J1=8.6 Hz, Jr:2.1 Hz). 7.58 
(lH, d, J=8.4 Hz), 7.54 (lH, d, J=8.8 Hz), 7.18 (lH, d, J=2.3 
Hz), 6.55 (lH, dd, J 1=8.4 Hz, J2=2.3 Hz), 5.72 (2H, broad). 
C. Coupling 55 
The JXC>duct from Part B, (240 mg, 0.17 rnmol) and 
sodium nitrite (23 mg. 0.33 rnmol) were dissolved in water 
(50 mL). The solution was then poured into a mixture of ice 
and concentrated hydrochloric acid (0.1 mL. 0.1 g, 0.33 
mmol) and stirred for 30 minutes. A second solution was 60 
made from 8-hydroxyquinoline-5-sulfonic acid monohy-
drate (81 mg, 0.33 rnmol) and sodium carbonate (38 mg, 
0.33 mmol) in water (20 mL). While cooled in an ice bath, 
the two solutions were mixed and stirred for an hour. The 
mixture was adjusted to pH 8 by the addition of a small 65 
amount of sodium hydroxide solution. The coupling product 
(240 mg, 62%) was separated by salting out with sodium 
activity," J. Natl Cancer Inst., 81, 577-586 (1989)) is 
designed to detect agents acting at any stage of the virus 
reproductive cycle. The assay includes the killing of T4 
lymphocytes by IIlV. Pursuant to the test, small amounts of 
IIlV are added to cells, and a complete cycle of virus 
reproduction is necessary to obtain the required cell killing. 
Agents that interact with virions, cells, or virus gene-
products to interfere with viral activities will protect cells 
from cytolysis. The system is thus designed to detect anti-
IIlV activity. However, compounds that are chemically 
labile or are rapidly metabolized in the culture conditions 
may not show activity in this screen. All tests are compared 
with at least one positive (e.g., AZf-treated) control done at 
the same time under identical conditions. 
The Procedure: 
1. Candidate agent is dissolved in dimethyl sulfoxide (unless 
otherwise instructed) and then diluted 1: 100 in cell culture 
medium before preparing serial half-log10 dilutions which 
are then to 96-well microfilter plates. T4 lymphocytes 
(CEM cell line) are added, and after a brief interval IIlV-1 
is added to all wells, resulting in a 1:200 final dilution of 
the compound. Uninfected cells with the compound serve 
as a toxicity control, and infected and uninfected cells 
without the compound serve as basic controls. 
2. Cultures are incubated at 37° C. in a 5% carbon dioxide 
atmosphere for 6 days. 
3. The tetrazolium salt, X'IT, is added to all wells, and 
cultures are incubated to allow formazan color develop-
ment by viable cells. 
4. Individual wells are analyzed spectrophotometrically to 
quantitate formazan production, and in addition are 
viewed microscopically for detection of viable cells and 
confirmation of protective activity. 
5. Drug-tested virus-infected cells are compared with drug-
treated noninfected cells and with other appropriate con-
trols (untreated infected and untreated noninfected cells, 
drug-containing wells without cells, etc.) on the same 
plate. 
6. Data are reviewed in comparison with other tests done at 
the same time and a determination about activity is made. 
The aroylaniline compounds of the present invention were 
tested for anti-IIlV activity according to the above proce-
dure. FlGS. 1--6 represent test results of the aroylaniline 
compounds of Compounds 1, 3, 13, 14, 29 and 32. 
5,681,832 
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FIGS. 1 to (i display a plot of the log10 of the concentra-
tions (as µg/mL or molar as shown) of the aroylaniline 
compounds, Compounds 1, 3, 13, 14, 29 and 32, against the 
measured test values expressed as a percentage of the 
uninfected, untreated control values. The solid line depicts 
the percentage of surviving RN-infected cells treated with 
sample (at the indicated concentration) relative to 
uninfected, untreated controls. Thus, the solid line expresses 
the anti-HN activity of the compound. The dashed line 
depicts the percentage of surviving uninfected cells treated 
with the compound relative to the same uninfected, 
untreated controls. Thus, the dashed line expresses the 
growth inhibitory properties of the compound. The viral 
cytopathic effect of the compound is indicated by a dotted 
reference line. The dotted reference line shows the extent of 
destruction of cells by the virus in the absence of treatment 
and is used as a quality control parameter. Survival values of 
this parameter less than 50% are considered acceptable in 
the current protocol. Approximate values for 50% effective 
concentration (ECso) have been calculated for each test and 
are set forth for these Compounds in Tables 2-7, respec-
tively. 
Table 2 represents the in vitro anti-HN data for the graph 
shown in FIG. 1. 
TABLE2 
Summary 
Concentra- Dose 
Index lion (Molar) 
IC50 (Molar) 1.20 x 10-C 6.35 x 10-8 
EC50 (Molar) 1.44 x lo-<' 2.00 x 10-7 
1150 (IC/EC) 8.28 x 10"1 6.34 x 10-7 
Conclusion 2.00 x 10...,; 
CONFIRMED ACTIVE 6.33 x 10...,; 
2.00 x 10_,, 
6.32 x 10-<1 
2.00 x 10-< 
Percent 
of 
Protec-
lion 
-5.09 
5.09 
3.41 
68.63 
121.16 
107.11 
85.61 
-25.97 
Percent of 
Control 
Un-
Infected infected 
20.13 97.61 
V.87 102.04 
26.59 105.10 
76.16 106.46 
116.08 117.18 
105.40 108.84 
89.06 104.08 
4.26 6.47 
Table 3 represents the in vitro anti-HN data for the graph 
shown in FIG. 2. 
TABLE3 
Percent Pen:cnt of 
Summary of Control 
Concentra- Dose Protec- Un-
Index lion (Molar) lion Infected infected 
IC50 (Molar) >5.00xl~ 1.58 x 10-8 0.19 4.18 110.80 
ECSO (Molar) 4.06 x lo-<' 5.02 x 10-a 0.51 4.49 95.85 
1150 (IC/EC) >1.23 x 10"1 1.58 x 10-7 -1.29 2.76 94.42 
Conclusion 5.01x10-7 2.00 592 97.72 
CONFIRMED ACTIVE 1.58 x 10...,; 0.19 4.18 95.67 
5.00 x 10...,; 61.15 62.70 97.00 
1.58 x 10_,, 92.90 93.18 103.32 
5.00 x 10_,, 90.76 91.13 97.98 
Table 4 represents the in vitro anti-HN data for the graph 
shown in FIG. 3. 
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TABLE4 
Percent Percent of 
Sunnnary of Control 
Concentra- Dose Protec- Un-
Index lion (Molar) lion Infected infected 
IC50 (Molar) 2.90 x 10--' 6.35 x 10-8 15.57 35.83 86.36 
ECSO (Molar) 1.05 x lo-<' 2.00 x 10-7 -17.92 10.38 90.55 
1150 (IC/EC) 2.78 x 10"1 6.34 x 10-7 24.57 42.67 92.22 
Conclusion 2.00 x 10...,; 84.38 88.13 110.93 
CONFIRMED ACTIVE 6.33 x 10...,; 133.79 125.68 117.81 
2.00 x 10-> 67.54 75.33 73.70 
6.32 x 10-> 29.43 1.63 0.37 
2.00 x 10-< -28.03 2.70 2.05 
Table 5 represents the in vitro anti-HN data for the graph 
shown in FIG. 4. 
TABLE5 
Percent Pen:cnt of 
Snunnarv of Control 
Concentra- Dose Pro tee- Un-
Index lion (Molar) lion . Infected infected 
IC50 (Molar) 1.65 x 10--' 6.35 x 10-8 16.02 18.54 80.16 
ECSO (Molar) 8.05 x 10--7 2.00 x 10-1 17.57 20.04 8892 
1150 (ICJEC) 2.05 x 10"2 6.34 x 10-7 24.99 V.24 121.68 
Conclusion 2.00 x 10...,; 146.91 145.50 205.56 
CONFIRMED ACTIVE 6.33 x 10...,; 150.93 149.40 220.68 
2.00 x 10_,, 16.58 19.08 15.48 
6.32 x 10_,, 6.56 9.36 2.52 
2.00 x 10-< 27.65 29.82 -0.84 
Table 6 represents the in vitro anti-HN data for the graph 
shown in FIG. 5. 
TABLE6 
Percent Percent of 
Swmnary of Control 
Concentra- Dose Protec- Un-
Index lion (Molar) lion Infected infected 
IC50 (Molar) >2.20 x 10-C 6.35 x 10-8 -3.31 3.92 93.21 
ECSO (Molar) 1.25 x 10--' 2.00 x 10-1 -1.09 5.99 93.77 
1150 (IC/EC) >1.61 x 10"1 6.34 x 10-7 -0.52 6.52 92.80 
Conclusion 2.00 x 10...,; 0.58 7.54 95.15 
CONFIRMED ACTIVE 6.33 x 10...,; 2.47 9.30 96.67 
2.00 x 10_,, 83.30 84.47 99.02 
6.32 x 10_,, 92.72 93.23 100.14 
2.00 x 10-< 79.66 81.08 92.95 
Table 7 represents the in vitro anti-HN data for the graph 
shown in FIG. (i. 
TABLE7 
Percent Pen:cnt of 
Sunnn!!!I of Control 
Concentra- Dose Pro tee- Un-
Index lion (Molar) lion Infected infected 
IC50 (Molar) 1.51 x 10-C 6.36 x 10 .... -2.32 17.12 8394 
EC50 (Molar) 1.08 x lo-<' 2.01x10-7 --{i,05 14.10 82.40 
1150 (IC/EC) 1.40 x 10"2 6.35 x 10-7 9.69 26.85 95.11 
Conclusion 2.01x10...,; 97.49 97.97 9897 
CONFIRMED ACTIVE 6.34 x 10...,; 106.98 105.65 94.34 
2.00 x 10-0 115.65 112.68 98.84 
5,681,832 
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TABLE ?-continued 
Percent Percent of 
§!•mpry of Control 
5 
Coocentra- Dose Pro!«- Un-
Index tion (Molar) tion Infected infected 
6.33 x 10~ 118.99 115.38 95.50 
2.00 x 104 52.90 61.85 35.45 
10 
As illustrated in FIGS. 1-(i and Tables 2-7, the aroyla-
niline compounds of the present invention are effective in 
protecting cells from cytolysis. Their therapeutic index, 1150 
(IC/EC) is indicated on their graphs and in their respective 15 
tables. 
All references cited herein are incorporated in their entire-
ties by reference. 
28 
-continued 
R3 C(=Z)-
R2 RS 
R1, R2, R3, R4. Rs and R6 are each independently -H , 
--OH, a halogen, -NH2, -NHCH3, -N(CH3h, 
-CHO, CH30-, -S03 .E, -N02, --C02.E, -PO 
(O)z2.E, -CH20H, --CH2SCH2COR7, --CH2S-
C2H4COR7, -CH2S-CH(C02H)CH 2 COR7, 
-CH 2 S-CH(C0 2 H)CH 2 C0 2 R 7 , 
-CH2SCH2 CO:zR_7, -CH2SC2H4C02R7 or 
While this invention has been described with emphasis 
upon preferred embodiments, it will be obvious to those 20 
skilled in the art that variations in the preferred compounds 
and methods may be used and that it is intended that the 
invention may be practiced otherwise then as specifically 
described herein. Accordingly, this invention includes all 25 
modifications encompassed within the spirit and scope of the 
invention as defined by the following claims. 
wherein E represents H, lithium. sodium, potassium, 
ammonium, magnesium, (HOC2H4hNH, (CH3)JNH, 
30 CH3NH(C2H40Hh, (CH3)4N-, or HN-methylglucamine 
and wherein R7 is H, methyl, ethyl, benzyl, --NH2, 
-NHCH3 , or -NHC2Hs; 
What is claimed is: 
1. An aroylaniline compound having the formula: 
(I) 
wherein R is -H, -S03.E, 
-N02 , or a halogen; 
Q is 
35 
40 
Rs 45 
Yis 
R2 
Rl~R3 
-H, -CO, -CS, v_ C(=Z)-, 
R3 C(=Z)- R4 
50 
55 
60 
X is -CH=CH-, -CH 2 CH 2-, -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
-S02-, -NH-, --CH2- or cyclopropyl; 
Z is oxygen or sulfur; and 
n is 1 or 2, but when n is 1, Y is H, 
R2 
Rl~R3 
v_ C(=Z)-, 
R3 C(=Z)- R4 
and when n is 2, Y is -CO or -CS. 
2. The aroylaniline compound of claim 1 wherein the 
compound has the formula: 
5,681,832 
29 
SO:iNa 
''NH sor 
- \9J' SO:iNa OH - ' . 
3. The aroylaniline compound of claim 1 wherein the 
compound has the fonnula: 
HO N _ 
NH-C-HN II 
0 
4. The aroylaniline compound of claim 1 wherein the 
compound has the fonnula: 
30 
5. The aroylaniline compound of claim 1 wherein the 45 
compound has the fonnula: 
6. The aroylaniline compound of claim 1 wherein the 60 
compound has the fonnula: 
30 
5,681,832 
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7. A pharmaceutical composition comprising the aroyla-
niline compound of claim 2 and a pharmaceutically accept-
able carrier. 
8. A pharmaceutical composition comprising the aroyla-
niline compound of claim 3 and a pharmaceutically accept-
able carrier. 
20 
9. A pharmaceutical composition comprising the aroyla-
niline compound of claim 4 and a pharmaceutically accept- 25 
32 
-continued 
able carrier. y is 
11. A phannaceutical composition comprising the aroy-
laniline compound of claim 5 and a pharmaceutically 
acceptable carrier. 
11. A pharmaceutical composition comprising the aroy-
laniline compound of claim 6 and a pharmaceutically 
acceptable carrier. 
12. The aroylaniline derivative of claim 1, wherein· 
Y is selected from the group consisting of: 
-H, -co, -cs, or 
30 
35 
R2 
-H, -co, -cs, Rl~R3 u_ C(=Z)-' 
Rl C(=Z)-
·R1, R2, R3 , R4, R5 and R6 are each independently -H, 
--OH, a halogen, -NH2, -NHCH3 , -N(CH3)z, 
13. A pharmaceutical composition comprising a phanna- 45 
ceutically acceptable carrier and an aroylaniline compound 
having the structural formula: 
-CHO, CH30--, -S03 .E, -N02, -C02 .E, -PO (0)2.2E, -CH20H, -CH2SCH2COR7, -CH2S-
C2H4COR7, -CH2S-CH(C02H)CH2 COR7, 
-CH 2 S-CH(C0 2 H)CH 2 C0 2 R 7 , 
wherein R is -H, -S03 .E, 
-N02, or a halogen; 
Q is 
(I) 
R\ or 
-CH2SCH2CO;zR.7, -CH2SC2H4C02R7 or 
50 SOJll 
W~-
OH 
wherein E represents H, lithium, sodium, potassium, 
ammonium, magnesium, (HOC2H4)JNH, (CH3hNH, 60 CH3NH(C2H40H)z, (CH3 )4N-, or HN-methylglucamine 
and wherein R7 is H, methyl, ethyl, benzyl, -NH2, 
-NHCH3 , or -NHC2H5 ; 
65 
X is -CH=CH-, -CH2CH2-, -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
-S02-, -NH-, -CH2- or cyclopropyl; 
Z is oxygen or sulfur; and 
5,681,832 
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n is 1 or 2, but when n is 1, Y is H, 
-continued 
R3 C(=Z)- R• 
R2 R3 
Rl~R3 R2 
u_ C(=Z)-' 
C(=Z)- R4 
5 
10 R1, R2, R3 , R4, R5 and R6 are each independently -H, 
-OH, a halogen, -NH2, -NHCH3 , -N(CH3h, 
R2 
-CHO, CH30.-, -S03 .E, -N02, -C02.E, -PO 
(Oh2E, -CH20H, -CH2SCH2COR7, -CH2S-
C2H4COR7, -CH2S-CH(C02H)CH2COR7, 
15 
- C H 2 S - C H ( C 0 2 H ) C H 2 C 0 2 R 7 , 
-CH2SCH2C0~7, -CH2SC2H4C02R7 or 
and when n is 2, Y is -CO or -CS. 
14. A method for treating a viral infection of a host which 20 
comprises administering to said host an antiviral effective 
amount of an aroylaniline compound having the structural 
formula: 
(I) 25 
wherein R is -H, -S03 .E, -C02.E, -PO(Oh.2E, 
-N02 , or a halogen; 
Q is 
R5,or 
R6 
R2 
Yis 
R2 
30 
35 
40 
45 
50 
S03il 
cQN,-
OH 
wherein E represents H, lithium, sodium, potassium, 
ammonium, magnesium, (HOC2H4hNH, (CH3 hNH, 
CH3NH(C2H40Hh, (CH3 )4N-, or HN-methylglucamine 
and wherein R7 is H, methyl, ethyl, benzyl, -NH2 , 
-NHCH3, or -NHC2H5; 
X is -CH=CH-, -CH2CH2-, -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
-S02-, -NH-, -CH2- or cyclopropyl; 
Z is oxygen or sulfur; and 
n is 1 or 2, but when n is 1, Y is H, 
R2 R3 C(=Z)- R4 
"'():" 
- C(=Z)-' 
R2 R5,or 
RI R6 
R3 R4 
R2 Rs· 
RI R6 
and when n is 2, Y is -CO or -CS. R'D:R3 55 15. A method for inhibiting replication of a retrovirus 
-H, -co, -cs, , 
- C(=Z)-
C(=Z)- R4 
RI 
60 
65 
comprising contacting said retrovirus with a retrovirally 
effective amount of an aroylaniline compound having the 
structural formula: 
(I) 
wherein R is -H, -S03.E, -C02.E, -PO(Oh.2E, 
-N02, or a halogen; 
5,681,832 
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Q is 
R2 Rl 
··n··. R2 5 
Rl 
R3 
R• 10 
R2 Rs 
Rl R6 
wherein E represents H, lithium, sodium, potassium, 
ammonium, magnesium, (HOC2H4 )JNH, (CH3hNH, 
CH3NH(C2H40Hh, (CH3 ) 4N-, or HN-methylglucamine 
and wherein R7 is H, methyl, ethyl, benzyl, -NH2 , 
15 
-NHCH3 , or -NHC2H5 ; 
Yis 
R2 
RlnR3 
-H, -co, -cs, ' 
- C(=Z)-
Rl C(=Z)- R4 
R2 R', or 
Rl R6 
Rl C(=Z)- R• 
R2 R'; 
Rl R6 
R1, R2 , R3 , R4 , R 5 and R6 are each independently -H, 
-OH, a halogen, -NH2 , -NHCH3 , -N(CH3h, 
-CHO, CH30-, -S03.E, -N02 , -C02 .E, -PO 
20 
25 
30 
35 
40 
(0)2 .2E, -CH20H, -CH3SCH2COR7, -CH2S-
C2H4COR7, -CH 2 S-CH(C0 2H)CH 2 COR7, 45 
-CH 2 S-CH(C0 2 H)CH 2 C0 2 R 7 , 
-CH2SCH2 COiR7, -CH2SC2H4C02R7 or 
60 
X is -CH=CH-, -CH2 CH 2-, -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
-S02-, -NH-, -CH2- or cyclopropyl; 
Z is oxygen or sulfur; and 
n is 1 or 2, but when n is 1, Y is H, 
R2 Rl 
Rl~R3 R2 
v_ C(=Z)-' 
C(=Z)- R4 
RS, or 
and when n is 2, Y is -CO or -CS. 
16. The method of claim 14, wherein the viral infection is 
an HIV infection. 
17. The method of claim 16, wherein the aroylaniline 
compound is a compound having the formula: 
18. The method of claim 16, wherein the aroylaniline 
compound is a compound having the formula: 
5,681,832 
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S03- NH-C-HN II 
NH 0 
I 
c 
~ 
0 
N OH 
19. The method of claim 16, wherein the aroylaniline 
compound is a compound having the formula: 
20. The method of claim 16, wherein the aroylaniline 
compound is a compound having the formula: 
21. The method of claim 16, wherein the aroylaniline 
compound is a compound having the formula: 
22. The method of claim 15, wherein said retrovirus is a 
human immunodeficiency virus. 
30 
38 
23. A method for treating a retroviral infection in a 
mammal comprising administering a retrovirally effective 
amount of an aroylanilline compound having the structural 
formula: 
5,681,832 
39 40 
and wherein R7 is H, methyl, ethyl, benzyl, -NH2, 
(I) -NHCH3 , or -NHC2Hs; 
X is -CH=CH-, -CH2 CH 2 , -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
5 -S02-, -NH-, ---CH2- or cyclopropyl; 
Z is oxygen or sulfur; and 
where R is -H, -S03 .E, ---C02.E, -PO(O)i.2E, -N02, n is 1 or 2, but when n is 1, Y is H, 
or a halogen; 
Qis w 
R2 Rl 
··n ... R2 R5,or 15 
Rl Rl 
"D:" 
- C(=Z)-' 
Rl 
RI R6 
Rl 
Rl C(=Z)- R• 
Rl R• Rl R'· 
20 
Rl R' 
RI R6 
RI R6 and when n is 2, Y is --CO or --CS. 
25 24. The method of claim 23, wherein said mammal is a 
Yis 
Rl 
human. 
25. The method of claim 24, wherein said retroviral 
infection is an HN infection. 
R'D:R3 30 
26. A method for inhibiting replication of a virus in vitro 
comprising contacting said virus with an anti-virally effec-
tive amount of an aroylaniline compound having the struc-
tural formula: 
-H, -co, -cs, , 
- C(=Z)-
Rl C(=Z)- R4 
35 
(I) 
Rl R5, or 
Rl R6 
Rl C(=Z)- R• 
40 
wherein R is -H, -S03 .E, ---C02 .E, -PO(O)i.2E, 
-N02, or a halogen; 
Rl R'; 
45 
Rl R6 
R1, R2, R3 , R4, Rs and R6 are each independently -H, 
-OH, a halogen, -NH2 , -NHCH3 , -N(CH3 ) 2 , 50 
--CHO, CH30-, -S03 .E, -N02 • ---C02 .E, -PO (0)2.2E, ---CH20H, ---CH2SCH2COR7, ---CH2S-
C2H4COR7, -CH2 S-CH(C0 2H)CH2COR7, 
-CH 2 S-CH(C0 2 H)CH~C0 2 R 7 , 
---CHiSCH2COiR.7 • ---CH2SC2H4COiR. or 55 
SOJH 
w .. - 60 
OH 
wherein E represents H, lithium, sodium, potassium, 65 
ammonium, magnesium, (HOC2H4hNH, (CH3hNH, 
CH~(Cili40H)2, (CH3 ) 4N-, or HN-methylglucarnine 
Q is 
Rl Rl R• 
··n ... Rl R5,or 
RI R6 
Rl R• 
Rl R' 
RI 
y is 
Rl 
RID:Rl 
-H, -co, -cs, , 
. - C(=Z)-
5,681,832 
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-continued 
R3 C(=Z)- R4 
5 
42 
(I) 
wherein R is -H, -S03 .E, -C02 .E, -PO(Oh2E, 
-N02, or a halogen; 
10 Q is 
R1, R2, R3 , R4, R5 and R6 are each independently -H, 
-OH, a halogen, -NH2, -NHCH3, -N(CH3h, 
-CHO, CH30-, -S03.E, -N02, -C02.E, -PO 
15 
(Oh2E, -CH20H, -CH2SCH2COR7, -CH2S- 20 
C2H 4COR7, -CH 2S-CH(C02H)CH2COR7, 
-CH 2 S-CH(C0 2 H)CH 2 C0 2 R 7 , 
-CH2SCH2CO;iR7, -CH2SC2H4C02R7 or 
SOJll 
W~-
OH 
25 
30 
wherein E represents H, lithium, sodium, potassium, 
ammonium, magnesium, (HOC2H4)JNH, (CH3)JNH, 
CH3NH(C2H40H)2, (CH3 )4N-, or HN-methylglucamine 35 
and wherein R7 is H, methyl, ethyl, benzyl, -NH2 , 
-NHCH3 , or -NHC2H5 ; . 
X is -CH=CH-, -CH2CH 2-, -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
-S02-, -NH-, --CH2- or cyclopropyl; 40 
Z is oxygen or sulfur; and 
n is 1 or 2, but when n is 1, Y is H, 
C(=Z)- R4 
45 
50 
R3· C(=Z)- R4 
55 
RI 
and when n is 2, Y is --CO or --CS. 
27. The method of claim 26, wherein said virus is a 60 
retrovirus. 
28. The method of claim 27, wherein said retrovirus is a 
human immunodeficiency virus. 
29. A method for preventing a mammal from being 
R2 R3 R4 
·ty". Rz RS, or 
RI R6 
R3 R4 
R2 RS 
Rl R6 
y is 
R2 
R1D:R3 
-H, -co, -cs, , 
- C(=Z)-
C(=Z)- R4 
R1, R2, R3 , R4, R5 and R6 are each independently -H, 
--OH, a halogen, -NH2, -NHCH3 , -N(CH3h, 
-CHO, CH30-, -S03.E, -N02, -C02.E, -PO 
(0)2.2E, --CH20H, --CH2SCH2COR7, --CH2S-
C2H4 COR7, -CH2S-CH(C02H)CH2COR7, 
-CH 2 S-CH(C0 2 H)CH 2 C0 2 R 7 , -CH2SCH2C0~7, -CH2SC2H4C02R7 or 
SO)li 
o).,_ 
OH 
infected by a herpes virus comprising administering a pro- 65 wherein E represents H, lithium, sodium, potassium, 
phylactively effective amount of an aroylaniline compound ammonium, magnesium, (HOC2H4)JNH, (CH3hNH, 
having the structural formula: CH3NH(C2H40Hh, (CH3 )4N-, or HN-methylglucamine 
5,681,832 
43 
and wherein R7 is H, methyl, ethyl, benzyl, -NH2, 
-NHCH3 , or -NHC2H5 ; 
44 
-continued 
Rl C(=Z)- R4 
X is -CH=CH-, -CH 2 CH 2-, -CONH-, 
-NHCONH-, -NHCSNH-, -S-, -SO-, 
-S02-, -NH-, --CH2- or cyclopropyl; 5 
Z is oxygen or sulfur; and 
n is 1 Cl" 2, but when n is 1, Y is H, 
R2 Rl 
Rl~Rl R2 
\J-._ C(=Z)-' 
C(=Z)- R4 10 
and when n is 2, Y is -CO or -CS. 
15 30. The method of claim 26, wherein said aroylaniline 
compound has the formula: 
SOJNa f '\ NH sor 
- \9J' SOJNa ! - '. 
HO N _ 
30 31. The method of claim 26, wherein said aroylaniline 
compound has the formula: 
* * * * * 
